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The Editorial on the Research Topic
Frontiers in Brain-Based Therapeutic Interventions and Biomarker Research in Child and 
Adolescent Psychiatry
Childhood psychiatric disorders present challenges given the heterogeneity of presentations, 
instability of phenotypes, and nascent understanding of neurodevelopment. Recent efforts, such as 
the National Institute of Mental Health Research Domain Criteria, aim to hone precision medicine 
approaches for psychiatric disorders (1). Elucidating the ontogeny of psychiatric illnesses and 
underlying neurobiology is a mandate for advancing modern clinical practice. Recent advances in 
neuroimaging, preclinical studies, genomics, and non-invasive brain stimulation may soon provide 
improved monitoring of development in health and disease. These tools also hold great promise for 
developing biological markers of illness that may be targeted through treatment innovation. This 
research topic surveys recent developmentally informed clinical neuroscience efforts focused on 
conditions that affect children and adolescents. Broadly, this includes studies focusing on neurode-
velopmental disorders, eating disorders, mood disorders, and treatment innovations.
NEUrodEVEloPMENtal diSordErS
Recent changes in descriptive diagnostic criteria, such as DSM-5 (2), aim to bridge basic science 
findings with clinical practice (3). Goldani et  al. examine existing literature focused on putative 
biomarkers of autism spectrum disorder (ASD). Markers of mitochondrial function, oxidative stress, 
genetic clustering, and inflammation are promising approaches. However, at present, there is insuf-
ficient evidence to embed these markers into clinical practice (Goldani et al.). In other efforts to 
better understand neurobiology in ASD and related neurodevelopmental disorders, Baribeau and 
Anagnostou review neuroimaging correlates of ASD and schizophrenia. Volumetric changes, corti-
cal thickness differences, and white matter changes in childhood onset schizophrenia (COS) appear 
to attenuate with age. Impaired local connectivity may also be coupled with amplified long-range 
connectivity in this condition. Neuroimaging findings in ASD collectively suggest an initial period 
of brain verdancy followed by dysmorphogenesis in adolescence. Furthermore in ASD, patterns of 
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local hyper-connectivity are coupled with impaired long-range 
neural communication (Baribeau and Anagnostou). Nagamitsu 
et al. present recent dimensional work with brain single-photon 
emission computed tomography (SPECT) in participants with 
attention deficit hyperactivity disorder (ADHD). Children with 
ADHD, and higher scores on the child behavior checklist-dysreg-
ulation profile had significantly increased 123I-iomazenil biding in 
the posterior cingulate cortex. These data suggest that GABAergic 
inhibitory neurons are involved in the pathophysiology of ADHD 
(Nagamitsu et al.).
aFFECtiVE diSordErS
Recent controversies surrounding the phenotyping of child-
hood mood disorders underscore the necessity of ongoing work 
focused on the neurobiological characterization of affective 
disorders during neurodevelopment (4). Henderson et al. exam-
ine white matter microorganization as assessed with diffusion 
tensor imaging (DTI) in adolescents with depression and healthy 
controls. Anhedonia and irritability were associated with unique 
neuroanatomical signatures. This promising early work suggests 
that prefrontal and limbic tracts are disrupted in depression 
and unique symptom presentations may have DTI signatures 
(Henderson et al.). Lee et al. examine brain function of healthy 
control participants, high-risk offspring, and youth with bipolar 
disorder by means of a meta-analytic approach. The authors 
postulated that greater activity in high-risk participants signifies 
potential compensatory mechanisms, whereas more widespread 
findings in bipolar patients signified chronic disease processes 
(Lee et  al.). Finally, Walker et  al. propose a compelling model 
for the mood disorder prodrome. These authors posit that early 
life stress, inflammation, and allosteric load are key contributors 
to disease burden, disease progression, and neuropathology 
(Walker et al.).
EatiNG diSordErS
Eating disorders are severely impairing psychiatric illnesses, with 
high mortality rates, and profound neurobiologic underpinnings 
(5). Herein, McAdams and Krawczyk describe findings from a 
study of patients with anorexia, patients with bulimia, and 
healthy controls. Participants were exposed to social attribution, 
social identity, and physical identity fMRI tasks. Consistently 
throughout each region of interest, average activation levels 
for bulimic participants were greater than the group of patients 
with anorexia, but less than healthy participants. The authors 
concluded that patients with eating disorders could have a 
similar biological substrate in terms of social functioning, yet a 
distinctive functional characterization is a plausible pursuit for 
future work (McAdams and Krawczyk). Nagamitsu et  al. also 
present intriguing work focused on developing SPECT biomark-
ers to guide the treatment of children with anorexia nervosa. 
In children with anorexia nervosa, decreased 123I-iomazenil 
binding in the anterior cingulate and left parietal cortices was 
associated with a suboptimal response to treatment. Successful 
weight restoration was associated with increased relative binding 
of 123I-iomazenil in the posterior cingulate and occipital cortices 
(Nagamitsu et al.).
trEatMENt iNNoVatioN iN  
CHildrEN aNd YoUtH
Transcranial magnetic stimulation (TMS) is a powerful thera-
peutic and neurophysiological probe. Neurocognitive outcomes 
are key both in terms of safety and for intervention develop-
ment, as they may serve as optimal clinical outcome measures 
in youth (6, 7). Wall et al. report on a study in which eighteen 
depressed adolescents received 30 sessions of 10-Hz rTMS, 
applied to the left dorsolateral prefrontal cortex. Participants 
demonstrated improvements in delayed verbal recall and 
memory. Furthermore, there were no decrements in other neu-
rocognitive dimensions (Wall et  al.). Desarkar et  al. postulate 
that imbalances in excitatory and inhibitory neurotransmission 
could underlie aberrant neuroplasticity in ASD. At the receptor 
level, this may involve excessive NMDA and deficient GABA-
mediated neurotransmission. Interventions with high frequency 
rTMS may have a role in stabilizing dysregulated neuroplasticity 
in ASD (Desarkar et al.).
In conclusion, the synthesis of neuroscience with child and 
adolescent psychiatry is yielding important discoveries and new 
directions for treatment innovation. However, we have yet to make 
the discoveries necessary to bring neuroscience research into the 
clinical realm through specific biomarker discovery that could 
pave the way for precision medicine where biomarkers are profiled 
in the clinic and individualized treatments are selected to optimize 
neurodevelopmental trajectories, mitigate the long-term effects 
of psychiatric illness, and maximize functioning for individuals. 
Novel research tools, innovative study designs that go beyond the 
case–control model, longitudinal research that identifies develop-
mental trajectories within heterogeneous conditions, and large-
scale studies with the power to detect small effects are likely the 
next frontier in research focused on advancing our understanding 
of neurobiological underpinnings and developing biologically 
informed treatments for children and youth with mental illness.
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